• Ascendis Pharma swung to a third-quarter 2026 net profit of EUR 73.97 million from a year-earlier loss.
• Revenue climbed 73% year over year to EUR 369.66 million, primarily driven by continued growth in YORVIPATH global sales.
• Operating cash flow totaled EUR 189 million; full-year 2026 operating cash flow is expected to reach at least EUR 600 million.
• TransCon CNP's final European Commission decision is expected in Q4 2026, with a German launch planned for Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120730PRIMZONEFULLFEED9876264) on November 12, 2026, and is solely responsible for the information contained therein.